Summary
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood
cells). Most trial participants with MM relapse (cancer has come back) or become non-
responsive to treatment and remission gets shorter after each line of treatment. This is a
study to determine recommended Phase 2 dose and change in disease symptoms of eftozanermin
alfa in combination with bortezomib and dexamethasone to assess how efficient the treatment
is in adult participants with relapsed/refractory (R/R) MM.
Eftozanermin alfa (ABBV-621) is an investigational drug being developed for the treatment of
R/R Multiple Myeloma (MM). Study doctors put the participants in 1 of the 2 groups, called
treatment arms. Each group receives a different treatment. Participants in one arm will
receive different doses of eftozanermin alfa in combination with bortezomib and dexamethasone
to determine phase 2 dose (RP2D). Participants in the other arm will receive eftozanermin
alfa at RP2D in combination with bortezomib and dexamethasone. Around 40 adult participants
with relapsed/refractory multiple myeloma will be enrolled at approximately 20 sites across
the world.
Participants will receive eftozanermin alfa as an infusion into the vein in combination with
bortezomib as an infusion into the vein or an injection under the skin and oral dexamethasone
tablets for 12 cycles. Each cycle is 21 days for cycles 1-8 and 35 days for cycles 9-12.
There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at a hospital or
clinic. The effect of the treatment will be checked by medical assessments, blood tests,
checking for side effects.